Orsini Specialty Pharmacy Logo
    • ABOUT
      • Accreditations
      • Leadership
      • Connect with Us
      • Careers
    • CENTERS OF EXCELLENCE
      • Cell and Gene Therapy
      • Acid Sphingomyelinase Deficiency
      • Alcohol Dependence
      • Alzheimer's Disease
      • Atypical Hemolytic Uremic Syndrome
      • Cartilage Disorders
      • CDKL5 Deficiency Disorder
      • Ceroid lipofuscinosis 2
      • Complex Partial Seizures
      • Cryopyrin-Associated Periodic Syndromes (CAPS)
      • Cystinuria
      • Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
      • Duchenne Muscular Dystrophy
      • Dystrophic Epidermolysis Bullosa (DEB)
      • Fabry Disease
      • Gaucher Disease Type 1
      • Growth Hormone Deficiency
      • Hemophilia
      • Hereditary Angioedema
      • Hereditary ATTR amyloidosis (hATTR)
      • Homozygous Familial Hypercholesterolemia (HoFH)
      • Idiopathic Pulmonary Fibrosis
      • Keratoconus
      • Long-Chain Fatty Acid Oxidation Disorders
      • Migraine
      • Mucopolysaccharidosis
      • Opioid Dependence
      • Paroxysmal Nocturnal Hemoglobinuria
      • Pompe Disease
      • Primary Hyperoxaluria Type 1
      • Recurrent C. difficile Infection
      • Recurrent Pericarditis
      • Schizophrenia
      • Spinal Muscular Atrophy
      • Tardive Dyskinesia
      • Tumor-induced Osteomalacia
      • Type 1 Diabetes
      • Venous Thromboembolism
      • X-linked Hypophosphatemia
    • PATIENTS
      • Patient Resources
      • Patient Journeys
        • Tommy (DMD)
        • Sienna and Wesley (SMA)
        • Erin (XLH)
        • Nicholas (MPS)
        • Robert (IPF)
        • Amy (HAE)
        • Joan (TD)
        • Wanda (TD)
        • Annabelle (MPS)
        • Austin & Max (DMD)
        • Lisa (HAE)
    • PRESCRIBERS
    • ENROLLMENT FORMS
    • PAYORS
    • PHARMA
    • BLOG

    Blog

    All Posts
      Orsini Specialty Pharmacy
      • Sep 29
      • 1 min read
      Orsini Specialty Pharmacy
      • Sep 29
      • 1 min

      Share Post

      Share Link

      Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease

      Orsini Specialty Pharmacy has been selected by Amicus Therapeutics to dispense Pombiliti™ (cipaglucosidase alfa-atga) and Opfolda™ (miglustat), a...

      Write a comment
      Orsini Specialty Pharmacy
      • Jun 15
      • 1 min read
      Orsini Specialty Pharmacy
      • Jun 15
      • 1 min

      Share Post

      Share Link

      Choosing a Specialty Pharmacy to Support Patients with Recurrent Pericarditis

      Recurrent Pericarditis (RP) is a painful auto-inflammatory cardiovascular disease that occurs when patients with acute pericarditis experience one or...

      Write a comment
      Orsini Specialty Pharmacy
      • Dec 15
      • 1 min read
      Orsini Specialty Pharmacy
      • Dec 15
      • 1 min

      Share Post

      Share Link

      Choosing a Specialty Pharmacy to Support Tardive Dyskinesia Patients

      Tardive Dyskinesia (TD) is a neurological movement disorder typically characterized by repetitive, involuntary movements of the jaw, lips, and tongue....

      Write a comment
      Orsini Specialty Pharmacy
      • Aug 18
      • 2 min read
      Orsini Specialty Pharmacy
      • Aug 18
      • 2 min

      Share Post

      Share Link

      Choosing a Specialty Pharmacy to Support Pompe Disease Patients

      Pompe disease is estimated at 1 in every 40,000 births. It is a rare, inherited disorder caused by the buildup of a complex sugar called glycogen and...

      Write a comment
      Orsini Specialty Pharmacy
      • Sep 28
      • 1 min read
      Orsini Specialty Pharmacy
      • Sep 28
      • 1 min

      Share Post

      Share Link

      Orsini Specialty Pharmacy Selected By Sanofi As A Limited Distribution Partner For Nexviazyme®

      Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that Sanofi has...

      Write a comment

      Subscribe for Updates

      Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.

      Learn More

      Recent Posts

      Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP

      Dec 4, 2023

      Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder

      Nov 20, 2023

      Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease

      Sep 29, 2023

      Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer

      Aug 30, 2023

      Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease

      Aug 23, 2023
      [Whitepaper] Payor Considerations   When Choosing a Specialty Pharmacy

      FOLLOW US

      linkedin
      e316f544f9094143b9eac01f1f19e697
      twitter

      CONTACT INFORMATION

      Address:
      1107 Nicholas Boulevard
      Elk Grove Village, IL 60007


      Phone:
      Corporate:  1-847-734-7373
      Pharmacy:  1-800-410-8575

      Pharmacy Fax: 1-847-879-9551

      Email: patientcare@orsinihc.com

       

      Click Here to Contact Us

      Hours:

      MON - FRI 8:00 AM - 5:30 PM

      ABOUT US

      • Enrollment Forms
      • Accreditations
      • HIPAA Notice of Privacy Practices
      • Privacy Notice
      • Careers
      • Blog

      WHO WE SERVE

      • Patients
      • Prescribers
      • Payors
      • Pharma

      ACHC
      ACHC-Accredited-Orphan-Drugs-Logo-1
      GoldSeal_National
      Accred-SPPRDOrsini02172023
      URAC Accreditation
      NABP
      © 2023 Orsini Pharmaceutical Services. All rights reserved.